BIOMAT Database Logo BIOMAT Database Logo

EVALUATION OF DEFEROXAMINE IN IRON OVERLOAD. 1964

Y F HWANG, and E B BROWN

UI MeSH Term Description Entries
D007501 Iron A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN. Iron-56,Iron 56
D010600 Pharmacology The study of the origin, nature, properties, and actions of drugs and their effects on living organisms. Pharmacologies
D003676 Deferoxamine Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. Desferrioxamine,Deferoxamine B,Deferoxamine Mesilate,Deferoxamine Mesylate,Deferoxamine Methanesulfonate,Deferoximine,Deferrioxamine B,Desferal,Desferioximine,Desferrioxamine B,Desferrioxamine B Mesylate,Desferroxamine,Mesilate, Deferoxamine,Mesylate, Deferoxamine,Mesylate, Desferrioxamine B,Methanesulfonate, Deferoxamine
D004369 Pentetic Acid An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium. DTPA,Diethylenetriamine Pentaacetic Acid,Pentetates,Penthanil,Ca-DTPA,CaDTPA,CaNa-DTPA,Calcium Trisodium Pentetate,DETAPAC,Indium-DTPA,Mn-Dtpa,Pentacin,Pentacine,Pentaind,Pentetate Calcium Trisodium,Pentetate Zinc Trisodium,Sn-DTPA,Zinc-DTPA,Indium DTPA,Pentaacetic Acid, Diethylenetriamine,Pentetate, Calcium Trisodium,Zinc DTPA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000740 Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN. Anemias
D014116 Toxicology The science concerned with the detection, chemical composition, and biological action of toxic substances or poisons and the treatment and prevention of toxic manifestations. Toxinology,Evidence Based Toxicology,Evidence-Based Toxicology,Based Toxicologies, Evidence,Based Toxicology, Evidence,Evidence Based Toxicologies,Evidence-Based Toxicologies,Toxicologies, Evidence Based,Toxicologies, Evidence-Based,Toxicology, Evidence Based,Toxicology, Evidence-Based
D014556 Urine Liquid by-product of excretion produced in the kidneys, temporarily stored in the bladder until discharge through the URETHRA.
D019190 Iron Overload An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989) Overload, Iron

Related Publications

Y F HWANG, and E B BROWN
Intravenous or subcutaneous deferoxamine for iron overload?
February 1978, The New England journal of medicine,
Y F HWANG, and E B BROWN
[Yersinia enterocolitica septicemia, iron overload and deferoxamine].
January 1995, La Revue de medecine interne,
Y F HWANG, and E B BROWN
Deferoxamine-chelatable iron in hemochromatosis and other disorders of iron overload.
March 1978, Mayo Clinic proceedings,
Y F HWANG, and E B BROWN
[Treatment of post-transfusion iron overload by deferoxamine].
February 1989, Archives francaises de pediatrie,
Y F HWANG, and E B BROWN
Using of deferasirox and deferoxamine in refractory iron overload thalassemia.
April 2021, Pediatrics international : official journal of the Japan Pediatric Society,
Y F HWANG, and E B BROWN
Continuous subcutaneous administration of deferoxamine in patients with iron overload.
August 1977, The New England journal of medicine,
Y F HWANG, and E B BROWN
Combating iron overload: a case for deferoxamine-based nanochelators.
May 2020, Nanomedicine (London, England),
Y F HWANG, and E B BROWN
Yersinia sepsis in patients with iron overload treated with deferoxamine.
June 1986, The New England journal of medicine,
Y F HWANG, and E B BROWN
Intraperitoneal deferoxamine therapy for iron overload in children undergoing CAPD.
June 1989, Kidney international,
Y F HWANG, and E B BROWN
Failure of deferoxamine to improve iron overload in chronic hemodialysis patients.
April 1990, The International journal of artificial organs,
Copied contents to your clipboard!